Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA

Corporate Breaking News

Home : Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA

Sep 28 2019	Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA
SHANGHAI and NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that a drug...


Source:https://www.prnewswire.com:443/news-releases/cellular-biomedicine-groups-rejoin-therapy-receives-stem-cell-drug-application-acceptance-for-phase-ii-clinical-trials-by-china-nmpa-300927246.html

Related News
» FORMER LOUSIANA ATTORNEY GENERAL'S LAW FIRM Kahn Swick & Foti, LLC Files a Securities Class Action Against Waitr Holdings Inc. f/k/a Landcadia Holdings, Inc. ‑‑ (NasdaqGS: WTRH) » GOL sobre Parceria com Delta